Richard Kuntz - Medtronic PLC President
| 2M6 Stock | EUR 81.88 0.73 0.88% |
President
Dr. Richard E. Kuntz, M.D., is Senior Vice President and Chief Scientific, Clinical and Regulatory Officer of the Company. Prior to that, he was Senior Vice President and President, Neuromodulation from October 2005 to August 2009 and prior to that, he was an interventional cardiologist and Chief of the Division of Clinical Biometrics at Brigham and Womens Hospital and Associate Professor of Medicine and Chief Scientific Officer of the Harvard Clinical Research Institute. since 2015.
| Age | 62 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
Medtronic PLC Leadership Team
Elected by the shareholders, the Medtronic PLC's board of directors comprises two types of representatives: Medtronic PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medtronic. The board's role is to monitor Medtronic PLC's management team and ensure that shareholders' interests are well served. Medtronic PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medtronic PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brett Wall, Executive Vice President and President Restorative Therapies Group | ||
| Bradley Lerman, Senior Vice President General Counsel, Corporate secretary | ||
| Scott Donnelly, Independent Director | ||
| Richard Anderson, Lead Independent Director | ||
| Hooman Hakami, Executive Vice President and Group President of the Diabetes Group | ||
| Elizabeth Nabel, Independent Director | ||
| Richard Kuntz, Senior Vice President and Chief Scientific, Clinical and Regulatory Officer | ||
| James Lenehan, Independent Director | ||
| John Liddicoat, Executive Vice President and President Americas Region | ||
| Robert White, Executive Vice President and President of Medtronic’s Minimally Invasive Therapies Group | ||
| Kevin Lofton, Independent Director | ||
| Craig Arnold, Independent Director | ||
| Kendall Powell, Independent Director | ||
| Sally Saba, Chief Inclusion and Diversity Officer | ||
| Denise OLeary, Independent Director | ||
| Omar Ishrak, Chairman of the Board, Chief Executive Officer | ||
| Sean Salmon, Executive Vice President and President, Cardiovascular Portfolio, Diabetes Operating | ||
| Carol Surface, Chief Human Resource Officer, Senior Vice President | ||
| Karen Parkhill, Chief Financial Officer, Executive Vice President | ||
| Michael Leavitt, Independent Director | ||
| Geoffrey Martha, Executive Vice President and President - Restorative Therapies Group | ||
| Randall Hogan, Independent Director | ||
| Andrea Goldsmith, Independent Director | ||
| Robert Hoedt, Executive Vice President and President - EMEAC | ||
| Michael Coyle, Executive Vice President Group President - Cardiac and Vascular Group |
Medtronic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medtronic PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Medtronic Stock Analysis
When running Medtronic PLC's price analysis, check to measure Medtronic PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medtronic PLC is operating at the current time. Most of Medtronic PLC's value examination focuses on studying past and present price action to predict the probability of Medtronic PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medtronic PLC's price. Additionally, you may evaluate how the addition of Medtronic PLC to your portfolios can decrease your overall portfolio volatility.